 |
||
 |
 |
 |
 |
||
 WINTER 2010 |
||
 |
|||||||||||||||||||||||||||||
UPCOMING EVENTS
IN THIS ISSUE
CONTACT US
|
Chemistry Playbook
Are you struggling with managing the linkages between your external suppliers? CML has teamed up with three highly respected companies to provide practical common sense solutions to expedite your drug development process; we call it Chemistry Playbook. CML is sponsoring a symposium in Boston on March 4th where we will unveil the Chemistry Playbook. Please join us at this event.
Click Here to read more and register
Coupling Agent T3P: An interesting non-toxic and economical alternativeDr. Arian van Eijk, Project Manager, CML Europe
A lot of interesting chemical entities contain amide moieties. Peptides are the most well-known ones. Peptide chemistry is well developed and these interesting molecules can be even produced in computerized reactor set-ups, where protection, coupling and deprotection is part of the chemical transformations applied.
CML is introducing a low cost small scale synthesis services initiative. Leveraging the company’s vast experience in chemical synthesis, advanced analytical techniques, and US-based location, CML will provide this expanded service offering starting February 2010.
| ||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||
 |
|||||||||||||||||||||||||||||
|
||||
|
New Appointments at CML
JAMES KANTER - Director of Business Development James joined CML as Director of Business Development in January of 2010. His unique combination of drug development expertise and vast network of contacts in the biotech sector make James a real asset to CML. He will be responsible for developing new business opportunities for CML, as well as providing guidance to the organization in strategic alliances and overall CMC management. James has over 15 years of experience as a process chemist and CMC expert in the biotech and pharmaceutical industry. He has been involved in the development of more than 25 small molecule compounds spanning the areas from late lead optimization through to commercial launch. This includes compounds in the areas of oncology, cardiovascular, CNS, anti-viral, anti-biotic, and pain therapeutics. He was instrumental in the establishment of several process and pharmaceutical science groups at such companies as Microcide Pharmaceuticals, COR Therapeutics, Millennium (now Takeda) and Exelixis. In addition he has consulted for virtual, small, and mid-sized biotechs with compounds at varying stages of clinical development.
James obtained his undergraduate and graduate degree at the University of Toronto doing work in the area of physical organic chemistry. James has numerous publications and patents spanning the areas of mechanistic, synthetic, and process chemistry.
|
|
||||
|
||||